ReviewDiagnostics (Basel, Switzerland)2021
Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects.
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- A Novel Risk Score Model for the Differential Diagnosis of Type 2 Diabetic Nephropathy: A Multicenter Study.Journal of diabetes research · 2023Trial
- Article
- Carotid plaque burden across the glycaemic spectrum: a cross-sectional study.BMC endocrine disorders · 2026Article
- Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm.Reviews in cardiovascular medicine · 2025Review
- Silane-crosslinked graphene oxide reinforced chitosan/sodium alginate hydrogel for controlled release of insulin.RSC advances · 2025Article
- Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications.Antioxidants (Basel, Switzerland) · 2025Review
- Risk prediction model for progression of type 2 diabetic nephropathy with and without metabolic syndrome: a retrospective cohort study.Frontiers in endocrinology · 2025Article
- The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease.Biomolecules · 2024Review
- Advances in the Insulin-Heart Axis: Current Therapies and Future Directions.International journal of molecular sciences · 2024Review
- Prevalence and Risk Factors of Chronic Kidney Disease in Patients With Type 2 Diabetes in China: Cross-Sectional Study.JMIR public health and surveillance · 2024Observational
- Advances in Nanomedicine for Precision Insulin Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Cardiac-Kidney-Liver (CKL) syndrome: the "real entity" of type 2 diabetes mellitus.Archives of medical science : AMS · 2024Article
- Chinese Healthcare Workers' Knowledge, Attitudes, and Practices in Diabetic Kidney Management: A Multi-Centered Cross-Sectional Study.Risk management and healthcare policy · 2024Article
- Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications.Current issues in molecular biology · 2023Review
- Cardio-Renal Metabolic Syndrome: Interdisciplinary Diagnostic Methods.Diagnostics (Basel, Switzerland) · 2023Article
- The Molecular Mechanism of Renal Tubulointerstitial Inflammation Promoting Diabetic Nephropathy.International journal of nephrology and renovascular disease · 2023Review
- Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Article
- Relationships between serum Klotho concentrations and cognitive performance among older chronic kidney disease patients with albuminuria in NHANES 2011-2014.Frontiers in endocrinology · 2023Article
- Albuminuria as a predictor of mortality in type II diabetic patients after living-donor liver transplantation.Annals of medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical significance of albuminuria in diabetic subjects and the impact of its reduction on the main cardiorenal outcomes by different drug classes are among the most interesting research focuses of recent years. Although nephrologists and cardiologists have been paying attention to the study of proteinuria for years, currently among diabetics, increased urine albumin excretion ascertains the highest cardio-renal risk. In fact, diabetes is a condition by itself associated with a high-risk of both micro/macrovascular complications. Moreover, proteinuria reduction in diabetic subjects by several treatments lowers both renal and cardiovascular disease progression. The 2019 joint ESC-EASD guidelines on diabetes, prediabetes and cardiovascular (CV) disease assign to proteinuria a crucial role in defining CV risk level in the diabetic patient. In fact, proteinuria by itself allows the diabetic patient to be staged at very high CV risk, thus affecting the choice of anti-hyperglycemic drug class. The purpose of this review is to present a clear update on the role of albuminuria as a cardio-renal risk marker, starting from pathophysiological mechanisms in support of this role. Besides this, we will show the prognostic value in observational studies, as well as randomized clinical trials (RCTs) demonstrating the potential improvement of cardio-renal outcomes in diabetic patients by reducing proteinuria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.